ResourcesHeadlineDark Gray3.00000000000000Resources
Arizona's Biomedical HubHTML ContentNavy1.00000000000000Arizona's Biomedical Hub<div class="ExternalClass78B4DD2EB29946DEB4169C22964C116D"><html> In a field as exciting and competitive as the biomedical sciences, every opportunity to excel must be taken. The City of Phoenix recognized the wide variety of institutions within the field, and took the opportunity to integrate them on a diverse, balanced biomedical campus. Nowhere else in the region can such a talented mix of doctors, researchers, innovators, educators, allied health professionals and thought leaders be found all at one address in Downtown Phoenix.<span id="ms-rterangepaste-end"></span> </html></div>1
Explore the PossibilitiesVideoLight Gray2.00000000000000Explore the Possibilities<div class="ExternalClass4B7E6E90CB4148F2BB86033BDF5B36BC"><html> <p> <span aria-hidden="true" id="ms-rterangepaste-start"></span><a href="https://www.youtube.com/watch?v=fL3bCjwkS0s" target="_blank">https://www.youtube.com/watch?v=fL3bCjwkS0s</a></p> </html></div>

 

 

About the City of PhoenixAbout the City of Phoenix1.00000000000000https://www.phoenix.gov/PencilIcons
Let the City of Phoenix Assist YouLet the City of Phoenix Assist You2.00000000000000https://www.phoenix.gov/econdev/IncentivesHandIcons
Workforce AvailabilityWorkforce Availability3.00000000000000http://www.arizonaatwork.com/phoenix/Bar GraphIcons
Cost of Doing Business in PhoenixCost of Doing Business in Phoenix4.00000000000000https://www.phoenix.gov/econdevsite/Documents/Cost%20of%20Doing%20Business%20Insert.pdfPeopleIcons
One Page SummaryOne Page Summary5.00000000000000https://www.phoenix.gov/econdevsite/Documents/PBC%20Insert.pdfMegaphoneIcons
IncubatorsIncubators6.00000000000000https://www.phoenix.gov/econdevsite/Documents/Incubators.pdfAvatarIcons

 

 

Beyond DNA: TGen points the way to enhanced precision medicine with RNA sequencingBeyond DNA: TGen points the way to enhanced precision medicine with RNA sequencing<div class="ExternalClassB345E43E51A14208AA3D9C70DF7B072E"><html> <div dir="ltr" style="text-align:left;" class="ExternalClass1A9E231B04D64CA58E0E5E8FF039BCAC"><span id="ms-rterangepaste-start"></span>​PHOENIX, Ariz. - March 21, 2016 - Uncovering the genetic makeup of patients using DNA sequencing has in recent years provided physicians and their patients with a greater understanding of how best to diagnose and treat the diseases that plague humanity. This is the essence of precision medicine.<br><br> Now, researchers at the <a target="_blank" href="https://www.tgen.org/home.aspx"><span style="text-decoration:underline;"><font color="#0066cc">Translational Genomics Research Institute (TGen)</font></span></a> are showing how an even more detailed genetic analysis using RNA sequencing can vastly enhance that understanding, providing doctors and their patients with more precise tools to target the underlying causes of disease, and help recommend the best course of action.<br><br> In their review, published today in the journal Nature Reviews Genetics, TGen scientists highlight the many advantages of using RNA-sequencing in the detection and management of everything from cancer to infectious diseases, such as Ebola and the rapidly spreading Zika virus.<br><br> RNA's principal role is to act as a messenger carrying instructions from DNA for the synthesis of proteins. Building on the insights provided by DNA profiling, the analysis of RNA provides an even more precise look at how cells behave and how medicine can intervene when things go wrong.<br><br> "RNA is a dynamic and diverse biomolecule with an essential role in numerous biological processes," said Dr. Sara Byron, Research Assistant Professor in TGen's Center for Translational Innovation, and the review's lead author. "From a molecular diagnostic standpoint, RNA-based measurements have the potential for broad application across diverse areas of human health, including disease diagnosis, prognosis, and therapeutic selection."<br><br> DNA (deoxyribonucleic acid) sequencing spells out -in order- the billions of chemical letters that make up the genes that drive all of our biologic make up and functions, from hair and eye color to whether an individual may be predisposed to cancer or other diseases.<br><br> RNA (ribonucleic acid) sequencing provides information on the genes that are actively being made into RNA in a cell and are important for cell function. While more complex, RNA holds the promise of more precise measurement of the human physical condition.<br><br> There simply are more forms, or species, that RNA takes, explains Dr. Byron. "RNA-sequencing provides an deeper view of a patient's genome, revealing detailed information on the diverse spectrum of RNAs being expressed."<br><br> One of the most promising aspects of RNA-based measurements is the potential of using extracellular RNA (exRNAs) as a non-invasive diagnostic indicator of disease. Monitoring exRNA simply takes a blood sample, as opposed to doing a tumor biopsy, which essentially is a minor surgery with greater risks and costs.<br><br> "The investigation of exRNAs in biofluids to monitor disease is an area of diagnostic research that is growing rapidly," said Dr. Kendall Van Keuren-Jensen, TGen Associate Professor of Neurogenomics, Co-Director of TGen's Center for Noninvasive Diagnostics, and one of the review's authors. "Measurement of exRNA is appealing as a non-invasive method for monitoring disease. With increased access to biofluids, more frequent sampling can occur over time."<br><br> The first test measuring exRNA was released earlier this year, the review said, for use measuring specific exRNAs in lung cancer patients. And, the potential for using RNA-seq in cancer is expanding rapidly. Commercial RNA-seq tests are now available, and provide the opportunity for clinicians to more comprehensively profile cancer and use this information to guide treatment selection for their patients, the review said.<br><br> In addition, the authors reported on several recent applications for RNA-seq in the diagnosis and management of infectious diseases, such as monitoring for drug resistant populations during therapy and tracking the origin and spread of the Ebola virus.<br><br> Using examples from discovery and clinical research, the authors also describe how RNA-seq can help guide interpretation of genomic DNA sequencing results. The utility of integrative sequencing strategies in research studies is growing across broad health applications, and points to the promise for incorporation of RNA-seq into clinical medicine, the review said.<br><br> The paper, Translating RNA-sequencing into Clinical Diagnostics: Opportunities and Challenges, was published online today in the journal Nature Reviews Genetics.<br><br> This review was funded by The Ben & Catherine Ivy Foundation of Scottsdale, the National Center for Advancing Translational Sciences, and a Stand Up To Cancer-Melanoma Research Alliance Melanoma Dream Team Translational Cancer Research Grant.<br><br> # # #<br>About TGen<br><br> Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a target="_blank" href="https://www.tgen.org/home.aspx"><span style="text-decoration:underline;"><font color="#0066cc">www.tgen.org</font></span></a>. Follow TGen on <a target="_blank" href="https://www.facebook.com/helptgen"><span style="text-decoration:underline;"><font color="#0066cc">Facebook</font></span></a>, <a target="_blank" href="https://www.linkedin.com/company/tgen"><span style="text-decoration:underline;"><font color="#0066cc">LinkedIn</font></span></a> and <a target="_blank" href="https://twitter.com/TGen"><span style="text-decoration:underline;"><font color="#0066cc">Twitter @TGen</font></span></a>.<br><br>Press Contacts:<br> Steve Yozwiak<br> TGen Senior Science Writer<br> 602-343-8704<br><a target="_blank" href="mailto:syozwiak@tgen.org"><span style="text-decoration:underline;"><font color="#0066cc">syozwiak@tgen.org</font></span></a><span id="ms-rterangepaste-end"></span></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></div> </html></div>
Arizona Bioscience Roadmap Report for 2015 ReleasedArizona Bioscience Roadmap Report for 2015 Released<div class="ExternalClass8DACC87BACA44642ABA8E3AA764D62EB"><html> <p></p><header class="entry-header" style="zoom:1;margin-bottom:20px;color:rgb(51, 51, 51);font-family:'helvetica neue', helvetica, arial, 'lucida grande', sans-serif;font-size:13px;line-height:19.5px;background-color:rgb(252, 252, 252);"><span id="ms-rterangepaste-start"></span><header class="entry-header" style="zoom:1;margin-bottom:20px;color:rgb(51, 51, 51);font-family:'helvetica neue', helvetica, arial, 'lucida grande', sans-serif;font-size:13px;line-height:19.5px;background-color:rgb(252, 252, 252);"><h1 style="border:0px;font-family:inherit;font-size:20px;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(59, 59, 59);line-height:1.35em;" class="entry-title"><a style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:inherit;" rel="bookmark" title="Permalink to Arizona Bioscience Roadmap Report for 2015 Released" href="http://www.azbio.org/arizona-bioscience-roadmap-report-for-2015-released" target="_blank">Arizona Bioscience Roadmap Report for 2015 Released</a></h1><div style="border:0px;font-family:inherit;font-size:12px;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(143, 143, 143);" class="entry-meta">Posted on <a style="border:0px;font-family:inherit;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(94, 94, 94);" rel="bookmark" title="12:02 pm" href="http://www.azbio.org/arizona-bioscience-roadmap-report-for-2015-released" target="_blank">Tue/29/March</a> <span style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;" class="byline">by <span style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;" class="author vcard"><a style="border:0px;font-family:inherit;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(94, 94, 94);" rel="author" title="View all posts by Joan Koerber-Walker" href="http://www.azbio.org/author/joan-koerber-walker" class="url fn n" target="_blank">Joan Koerber-Walker</a></span></span></div></header><div style="border:0px;font-family:'helvetica neue', helvetica, arial, 'lucida grande', sans-serif;font-size:13px;margin:0px;outline:0px;padding:0px;vertical-align:baseline;zoom:1;line-height:1.6em;color:rgb(102, 102, 102);background-color:rgb(252, 252, 252);" class="entry-content"><div style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;" data-summary="" data-link="http://www.azbio.org/arizona-bioscience-roadmap-report-for-2015-released" data-title="Arizona Bioscience Roadmap Report for 2015 Released" data-app="share_buttons" data-app-id="11403751" class="shareaholic-canvas"></div><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">By the Numbers:  Arizona bioscience job growth rate continues to outpace nation; Risk capital and university startups increase; Research dollars decline<span style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;"></span></p><div style="border:1px solid rgb(224, 224, 224);font-family:inherit;font-style:inherit;font-weight:inherit;margin:5px auto 30px;outline:0px;padding:8px;vertical-align:baseline;clear:both;max-width:100%;box-sizing:border-box;text-align:center;width:924px;" class="wp-caption aligncenter"><img style="max-width:100%;margin:5px;width:553px;" alt="Flinn RM Report Header 2015 Data" src="http://11759-presscdn-0-15.pagely.netdna-cdn.com/wp-content/uploads/2016/03/Flinn-RM-Report-Header-2015-Data.jpg" class="wp-image-14217 size-full" /><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;" class="wp-caption-text"><em style="border:0px;font-family:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;">The Phoenix-based Flinn Foundation commissioned the latest performance analysis as part of its coordination of Arizona’s Bioscience Roadmap, a long-term strategy to guide the state through 2025. The data released in the March 29 report, the first new metrics in two years, was provided by TEConomy Partners, formerly Battelle Technology Partnership Practice</em>. <strong style="border:0px;font-family:inherit;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;"><em style="border:0px;font-family:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;"><a style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(30, 115, 190);transition:all 0.2s ease;" target="_blank" href="http://11759-presscdn-0-15.pagely.netdna-cdn.com/wp-content/uploads/2016/03/2015-Bio-Progress-Report.pdf"><br>Click here to view/download the report</br></a>.</em></strong></p></div><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;"><strong style="border:0px;font-family:inherit;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;">Arizona’s bioscience industry has sustained its momentum and continues its long-standing trend of impressive job growth and high wages, according to a new report released by the Flinn Foundation on March 29, 2016.</strong></p><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">In addition, risk capital reached its highest figure in four years, and all measures of bioscience tech-transfer at Arizona universities are on the rise, with increases in startups, invention disclosures, patents, and licenses.</p><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">However, declining research dollars and expenditures raise concerns about the industry’s long-term capacity to keep adding jobs. National Institutes of Health grants and bioscience-related academic research-and-development expenditures both dropped in the latest year of data and are failing to keep pace with the nation.</p><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px 0px 0px 30px;vertical-align:baseline;">“There is evidence of innovation throughout Arizona and many positive economic signs, as the number of high-paying bioscience jobs continue to increase at an impressive rate,” said Mitch Horowitz, principal and managing director of TEConomy Partners. “However, we are concerned about the declines in NIH grants and R&D bio expenditures. If creative steps are not taken to reverse these trends, the state’s bioscience industry will be hard-pressed to keep growing.”</p><div style="border:1px solid rgb(224, 224, 224);font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 1.5em 1.5em;outline:0px;padding:8px;vertical-align:baseline;display:inline;float:right;max-width:100%;box-sizing:border-box;text-align:center;width:252px;" class="wp-caption alignright"><img style="max-width:100%;margin:5px;width:234px;" alt="Flinn Foundation Logo" src="http://11759-presscdn-0-15.pagely.netdna-cdn.com/wp-content/uploads/2011/05/flinn-foundation-logo.jpg" class="wp-image-588" /><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;" class="wp-caption-text">The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. In addition to advancing the biosciences, the foundation supports the Flinn Scholarship, a merit-based college scholarship program, arts and culture, and the Arizona Center for Civic Leadership. Learn more at <a style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(30, 115, 190);transition:all 0.2s ease;" target="_blank" href="http://www.flinn.org/">Flinn.org</a></p></div><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">Arizona’s Bioscience Roadmap was commissioned by the Flinn Foundation, a philanthropic grantmaking organization, in 2002 with a goal of increasing access for Arizonans to health innovations while diversifying and strengthening the state’s economy.</p><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">The long-term strategy was updated in 2014 to lead the state through 2025.</p><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">The Roadmap’s vision is for Arizona to become globally competitive and a national leader in in the biosciences in such fields as precision medicine, cancer, neurosciences, bioengineering, diagnostics, and agricultural biotechnology.</p><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;"><strong style="border:0px;font-family:inherit;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;">The most recent data shows:</strong></p><ul style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;list-style:square;"><li style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 0px 1.5em;outline:0px;padding:0px;vertical-align:baseline;"><strong style="border:0px;font-family:inherit;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;"> </strong>Arizona has added 36,700 bioscience jobs between 2002 and 2014, a 49 percent increase that brings today’s total to 110,410, including hospitals. Bioscience jobs have grown nationally at a 14 percent rate during this time.</li><li style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 0px 1.5em;outline:0px;padding:0px;vertical-align:baseline;">The average salary of a bioscience worker is $61,823, compared to $46,514 for the state’s private sector. Bioscience salaries have increased 50 percent since 2002.</li><li style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 0px 1.5em;outline:0px;padding:0px;vertical-align:baseline;">In 2015, Arizona saw its highest venture-capital investments for bioscience firms since 2011.The $82 million attracted is the third straight year of growth. It represents 0.56 percent of bioscience venture capital investments nationwide, the highest rate since 2011, but still well below the Roadmap’s goal.</li><li style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 0px 1.5em;outline:0px;padding:0px;vertical-align:baseline;">NIH funding was $151 million in 2015, down from $158 million in 2014. Since the start of the Roadmap, Arizona’s NIH annual funding has grown 12 percent compared to 40 percent for the top-10 funded states, which Arizona generally had met or exceeded during previous years. NIH grants are the gold standard in the biosciences.</li><li style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 0px 1.5em;outline:0px;padding:0px;vertical-align:baseline;">The value of bioscience R&D expenditures was $451 million in 2014, a slight drop from 2013. Arizona’s growth rate of 55 percent since 2002 falls short of the national growth rate of 78 percent.</li><li style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:0px 0px 0px 1.5em;outline:0px;padding:0px;vertical-align:baseline;">All measures of bioscience tech-transfer at Arizona universities are on the rise and are outperforming other university research disciplines in technology-transfer activities. University bio-related startups increased 24 percent in 2014-15 compared to the previous two years. During this same time, there was a 72 percent increase in patents and a 54 percent increase in invention disclosures.</li></ul><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">Setting aside hospitals, the largest bioscience subsector, Arizona has 24,040 bioscience jobs in 1,284 establishments, with an annual wage of $76,360.</p><blockquote style="border-width:0px 0px 0px 1px;border-left-style:solid;border-left-color:rgb(170, 170, 170);font-family:inherit;font-style:italic;font-weight:inherit;margin:1em 0px 1em 1em;outline:0px;padding:0px 0px 0px 1em;vertical-align:baseline;"><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">“We are very encouraged by the continued growth of the bioscience industry and our best risk-capital performance in four years,” said Ron Shoopman, chair of Arizona’s Bioscience Roadmap Steering Committee. “But leaders must emerge in the state to make the necessary strategic research investments. If not, we risk falling behind in not only developing new treatments, but in the commercialization of this research, which is crucial for job growth and building a critical mass of companies.”</p></blockquote><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">There were a number of major developments in 2015 through partnerships and collaborations involving private-sector companies, Arizona’s public universities, hospitals, and research labs. For instance, Arizona State University and Nantworks, led by billionaire physician and entrepreneur Patrick Soon-Shiong, announced they will build a research hub on the Phoenix Biomedical Campus. On the same campus, the University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center opened its new facility. Banner Health completed its acquisition of the University of Arizona Health Network and is investing in new hospital construction while becoming the academic partner of UA’s medical schools in Tucson and Phoenix.</p><blockquote style="border-width:0px 0px 0px 1px;border-left-style:solid;border-left-color:rgb(170, 170, 170);font-family:inherit;font-style:italic;font-weight:inherit;margin:1em 0px 1em 1em;outline:0px;padding:0px 0px 0px 1em;vertical-align:baseline;"><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">“As this new data shows, the investments made during the early years of the Roadmap are paying huge dividends for Arizona today,” said Jack B. Jewett, president & CEO of the Flinn Foundation. “The ongoing collaboration among our leading institutions has created an opportunity for innovation and for the bioscience industry to continue its momentum through the years.”</p></blockquote><p style="border:0px;font-family:inherit;font-style:inherit;font-weight:inherit;margin:1em 0px;outline:0px;padding:0px;vertical-align:baseline;">The next data report will be released in 2018.​</p></div><span id="ms-rterangepaste-end"></span><h1 style="border:0px;font-family:inherit;font-size:20px;font-style:inherit;margin:0px;outline:0px;padding:0px;vertical-align:baseline;color:rgb(59, 59, 59);line-height:1.35em;" class="entry-title"><br></br></h1></header></html></div>
TGen identifies 'hypervirulent' strain of strep outbreak in Arizona and the SouthwestTGen identifies 'hypervirulent' strain of strep outbreak in Arizona and the Southwest<div class="ExternalClass2E529122DBAA47B887750192F430050E"><html> <p> <strong>TGen identifies 'hypervirulent' strain of strep outbreak in Arizona and the Southwest</strong> </p> <p>The emm59 clone of Group A Streptococcus is a deadly type of bacterial infection related to a previous outbreak in Canada </p> <p> <strong>FLAGSTAFF, Ariz. - March 18, 2016 -</strong> The <a href="https://www.tgen.org/home.aspx" target="_blank"><span style="text-decoration:underline;">Translational Genomics Research Institute (TGen)</span></a> has helped state, local and tribal health officials identify an outbreak of "hypervirulent" strep bacteria in the American Southwest.<br> <br>Identified in Flagstaff, Ariz., from January to July 2015, this outbreak of the <em>emm59</em> clone of group A <em>Streptococcus</em> is directly related to cases identified recently in New Mexico. This strain type appears to have evolved from a nationwide outbreak in Canada that lasted from 2006-09, according to a report in the April issue of <em>Emerging Infectious Diseases</em>.<br> <br>"The presence of <em>emm59</em> in the southwestern United States poses a public health concern," said Dr. Paul Keim, Director of TGen's Pathogen Genomics Division (TGen North) in Flagstaff, and the senior author of the report.<br> <br>Group A strep is what commonly causes strep throat and sometimes can cause invasive skin infections. This <em>emm59</em>type of strep appears to more predominantly cause sever skin infections and fever that can present as necrotizing fasciitis, also known as flesh-eating bacteria, which can cause the loss of limbs and even death.<br> <br>Using advanced genomic sequencing, TGen investigators were able to track isolates of <em>emm59</em> throughout northern Arizona, and link it to cases in New Mexico and elsewhere, as part of the strain that came out of the Canada epidemic.<br> <br>"When compared with all other publically available U.S. <em>emm59</em> isolate genomes, a significant number of Flagstaff cases had group A strep strains that were identical. This tells us that we have an outbreak of this particularly nasty superbug," said Dr. David Engelthaler, Director of Programs and Operations at TGen North, and the lead author of the study.<br> <br>In conducting the analysis of this strep outbreak during the past year, TGen worked closely with doctors and epidemiologists at Northern Arizona Healthcare, the Arizona Department of Health Services, the Coconino County Public Health Services District, Northern Arizona University, and the Navajo Nation Division of Health.<br> <br>"Epidemiologic investigations are ongoing in Arizona to further determine the extent of the current strep outbreak, and to help minimize it's spread, especially to at-risk populations," said Dr. Engelthaler, who also is a TGen Associate Professor and Arizona's former State Epidemiologist.<br> <br>In addition, efforts are being made in education and outreach in Arizona especially among homeless and jail populations, which the study identified as vulnerable to this outbreak.<br> <br>Read the full report on the investigation here: <a href="http://wwwnc.cdc.gov/eid/article/22/4/15-1582_article" target="_blank"><span style="text-decoration:underline;">http://wwwnc.cdc.gov/eid/article/22/4/15-1582_article</span></a><br> <br># # #<br> <br><strong>About TGen</strong><br> Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a href="https://www.tgen.org/home.aspx" target="_blank"><span style="text-decoration:underline;">www.tgen.org</span></a>. Follow TGen on <a href="https://www.facebook.com/helptgen" target="_blank"><span style="text-decoration:underline;">Facebook</span></a>, <a href="https://www.linkedin.com/company/tgen" target="_blank"><span style="text-decoration:underline;">LinkedIn</span></a> and <a href="https://twitter.com/TGen" target="_blank"><span style="text-decoration:underline;">Twitter @TGen</span></a>.</p> </html></div>

© City of Phoenix Community and Economic Development